English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse
  1. View item / 
  2. Item Summary

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

Phenylalanine effects on brain function in adult phenylketonuria

MPS-Authors
/persons/resource/persons214625

Leks,  E
Department High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Max Planck Society;

/persons/resource/persons84187

Scheffler,  K
Department High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Max Planck Society;

External Resource

https://n.neurology.org/content/96/3/e399
(Publisher version)

Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Pilotto, A., Zipser, E., Leks, E., Haas, D., Gramer, G., Freisinger, P., et al. (2021). Phenylalanine effects on brain function in adult phenylketonuria. Neurology, 96(3), e399-e411. doi:10.1212/WNL.0000000000011088.


Cite as: https://hdl.handle.net/21.11116/0000-0007-4DA9-5
Abstract
Objective: To evaluate the relationship between circulating phenylalanine and brain function as well as neuropsychiatric symptoms in adult phenylketonuria patients.
Methods: In this prospective cross-sectional study, early-treated phenylketonuria patients older than 30 years and age and sex-matched controls were included. Extensive neurologic evaluation, neuropsychological and behavioral testing, sensory and motor evoked potentials, and MRI were performed. CSF concentrations of neurodegenerative markers were in addition evaluated in a subset of 10 patients.
Results: Nineteen phenylketonuria patients (median age 41 years) with different phenylalanine levels (median 873 μmol/L) entered the study. They showed higher prevalence of neurologic symptoms, cognitive and behavioral abnormalities, autonomic dysfunction, alterations in neurophysiologic measures and atrophy in putamen and right thalamus compared to controls. In CSF, Phenylketonuria patients exhibited higher Aβ1-42 (p = 0.003), T-Tau (p < 0.001) and P-Tau (p = 0.032) levels compared to controls. Plasma phenylalanine levels highly correlated with the number of failed neuropsychological tests (r = 0.64, p = 0.003), neuropsychiatric symptoms (r = 0.73, p < 001) motor evoked potential latency (r = 0.48, p = 0.030) and parietal lobe atrophy.
Conclusions: Our study provides strong evidence for a correlation between phenylalanine levels and clinical, neuropsychological, neurophysiologic, biochemical and imaging alterations in adult phenylketonuria patients.